Estrella Immunopharma Stock Probability of Future Stock Price Finishing Over 8.25
| ESLA Stock | 1.14 0.10 9.62% |
Estrella |
Estrella Immunopharma Target Price Odds to finish over 8.25
The tendency of Estrella Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over 8.25 or more in 90 days |
| 1.14 | 90 days | 8.25 | close to zero percent |
Based on a normal probability distribution, the odds of Estrella Immunopharma to move over 8.25 or more in 90 days from now is close to zero percent (This Estrella Immunopharma probability density function shows the probability of Estrella Stock to fall within a particular range of prices over 90 days) . Probability of Estrella Immunopharma price to stay between its current price of 1.14 and 8.25 at the end of the 90-day period is about 8.74 .
Given the investment horizon of 90 days Estrella Immunopharma has a beta of 0.16 suggesting as returns on the market go up, Estrella Immunopharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Estrella Immunopharma will be expected to be much smaller as well. Additionally Estrella Immunopharma has an alpha of 0.1686, implying that it can generate a 0.17 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Estrella Immunopharma Price Density |
| Price |
Predictive Modules for Estrella Immunopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Estrella Immunopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Estrella Immunopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Estrella Immunopharma is not an exception. The market had few large corrections towards the Estrella Immunopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Estrella Immunopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Estrella Immunopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.17 | |
β | Beta against Dow Jones | 0.16 | |
σ | Overall volatility | 0.14 | |
Ir | Information ratio | 0.01 |
Estrella Immunopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Estrella Immunopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Estrella Immunopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Estrella Immunopharma had very high historical volatility over the last 90 days | |
| Estrella Immunopharma may become a speculative penny stock | |
| Estrella Immunopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.31 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Estrella Immunopharma generates negative cash flow from operations | |
| Estrella Immunopharma has a frail financial position based on the latest SEC disclosures | |
| About 72.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks |
Estrella Immunopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Estrella Stock often depends not only on the future outlook of the current and potential Estrella Immunopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Estrella Immunopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 36.3 M |
Estrella Immunopharma Technical Analysis
Estrella Immunopharma's future price can be derived by breaking down and analyzing its technical indicators over time. Estrella Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Estrella Immunopharma. In general, you should focus on analyzing Estrella Stock price patterns and their correlations with different microeconomic environments and drivers.
Estrella Immunopharma Predictive Forecast Models
Estrella Immunopharma's time-series forecasting models is one of many Estrella Immunopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Estrella Immunopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Estrella Immunopharma
Checking the ongoing alerts about Estrella Immunopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Estrella Immunopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Estrella Immunopharma had very high historical volatility over the last 90 days | |
| Estrella Immunopharma may become a speculative penny stock | |
| Estrella Immunopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.31 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Estrella Immunopharma generates negative cash flow from operations | |
| Estrella Immunopharma has a frail financial position based on the latest SEC disclosures | |
| About 72.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks |
Check out Estrella Immunopharma Backtesting, Estrella Immunopharma Valuation, Estrella Immunopharma Correlation, Estrella Immunopharma Hype Analysis, Estrella Immunopharma Volatility, Estrella Immunopharma History as well as Estrella Immunopharma Performance. For information on how to trade Estrella Stock refer to our How to Trade Estrella Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. If investors know Estrella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Estrella Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.24) | Return On Assets (1.22) | Return On Equity (2.78) |
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Estrella Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Estrella Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Estrella Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.